AmpliPhi Biosciences appoints Alexander Gaidamaka as Vice President of CMC

Will oversee the compliant manufacture and quality assurance of phage-based therapeutics

AmpliPhi Biosciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, has appointed Dr Alexander Gaidamaka as the new Vice President of Chemistry, Manufacturing and Control.

Dr Gaidamaka brings extensive experience to the company, with more than 25 years in the life sciences sector. Prior to his role at AmpliPhi, he served as CEO and CSO of Personalized OncoTherapeutics. He has held executive R&D, product development and quality control roles at Pharma Green, Merial, Sanofi Pasteur, Bioniche Life Sciences and Biopharm JSC.

'As we drive our bacteriophage-based pipeline towards clinical development, we are expanding our senior team to add certain critical skills,' said M Scott Salka, CEO of AmpliPhi Biosciences. 'Alexander brings decades of experience and leadership to his role of overseeing the compliant manufacture and quality assurance of our phage-based therapeutics.'

You may also like

Regulatory

AmpliPhi Biosciences granted SME status by European Medicines Agency

AmpliPhi's product development programmes target infections that are often resistant to existing antibiotic treatments
Research & Development

Bacteria-eating viruses could aid battle against superbugs

University of Leicester team licenses technology to AmpliPhi, a pioneer in developing phage-based therapeutics
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now